Rapid Dose Therapeutics Corp (DOSE) Price & Analysis

Compare

8 Followers

DOSE Stock Chart & Stats

C$0.14

C$0.02(6.67%)

At close: Jan 08 4:00 PM EST

C$0.14

C$0.02(6.67%)

Day’s Range― - ―

52-Week RangeC$0.10 - C$0.24

Previous CloseN/A

Volume31.00K

Average Volume (3M)36.09K

Market Cap

C$14.51M

Enterprise ValueC$22.68M

Total Cash (Recent Filing)C$109.16K

Total Debt (Recent Filing)C$8.28M

Price to Earnings (P/E)―

Beta-0.07

Next Earnings

Jun 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding131,886,760

10 Day Avg. Volume35,351

30 Day Avg. Volume36,089

Financial Highlights & Ratios

PEG Ratio-0.38

Price to Book (P/B)-5.82

Price to Sales (P/S)18.01

P/FCF Ratio-8.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Oral Delivery PlatformThe company’s proprietary quick-dissolve oral film technology is a durable asset and differentiator in drug-delivery and consumer health. Licensing and formulation partnerships can generate recurring revenue and margin expansion without proportionate capex, supporting scalable growth if adoption continues.

Revenue Growth MomentumReported revenue growth (Fundamentals.RevenueGrowth ~72.8%) points to recent commercial traction and expanding customer adoption. Sustained top-line momentum over multiple quarters could enable operating leverage and absorption of fixed costs, improving long-term profit prospects if the trend persists.

Product-level Gross MarginsA roughly 30% gross margin indicates product economics that can support profitability as scale increases. With consistent revenue growth and distribution efficiencies, this margin base offers path to improved operating results through fixed-cost leverage and higher contribution per sale.

Bears Say

Negative Shareholders' EquityNegative equity combined with material debt is a structural balance-sheet weakness. It constrains financial flexibility, increases insolvency risk, and typically forces reliance on dilutive or costly financing, impairing the company’s ability to execute long-term commercialization plans without external support.

Ongoing Cash BurnPersistent negative operating and free cash flow demonstrates the company is not self-funding operations. Continued cash burn requires external capital, which can be dilutive or unavailable in tight markets, limiting investment in commercialization, R&D, and scaling over the medium term.

Deep Operating LossesVery large negative EBIT and net margins show core profitability issues relative to revenue. Until the company narrows losses through higher revenue, cost control, or margin expansion, sustained unprofitability threatens runway, investor support, and the feasibility of long-term strategic initiatives.

Rapid Dose Therapeutics Corp News

Rapid Dose Wins Key Indian Patent for QuickStrip Nicotine Oral Film

An announcement from Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) is now available. Rapid Dose Therapeutics has secured...

5d ago

Rapid Dose Therapeutics Advances Cannabinoid Studies for QuickStrip Drug Delivery Platform

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has issued an announcement. Rapid Dose Therapeutics has provided an update...

15d ago

Rapid Dose Therapeutics Lists on U.S. OTCQB to Broaden Investor Access

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an update. Rapid Dose Therapeutics Corp., a Canadian biotechnology...

27d ago

Rapid Dose Therapeutics Enters Brazil’s Medical Cannabis Market With QuickStrip Launch

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has issued an update. Rapid Dose Therapeutics has launched its co-branded...

28d ago

Rapid Dose Therapeutics Pays Convertible Note Interest in Shares

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an announcement. Rapid Dose Therapeutics Corp. will issue 362,708...

2M ago

Rapid Dose Therapeutics Extends Convertible Notes Maturity Date

An update from Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) is now available. Rapid Dose Therapeutics Corp. announced...

3M ago

Rapid Dose Therapeutics Extends Nicotine Partnership and Advances NicStrip™ Commercialization

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an announcement. Rapid Dose Therapeutics Corp. has announced a...

5M ago

Rapid Dose Therapeutics to Issue Shares for Debt Interest Payment

An update from Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) is now available. Rapid Dose Therapeutics Corp. announced...

5M ago

Rapid Dose Therapeutics Seeks Health Canada Approval for QuickStrip™ Nicotine

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has provided an announcement. Rapid Dose Therapeutics Corp. has submitted its...

7M ago

Rapid Dose Therapeutics to Issue Shares for Quarterly Interest Payment

Rapid Dose Therapeutics Corp ( ($TSE:DOSE) ) has issued an announcement. Rapid Dose Therapeutics Corp. announced its plan...

8M ago

DOSE FAQ

What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?

Rapid Dose Therapeutics Corp lowest stock price was C$0.10 and its highest was C$0.24 in the past 12 months.

What is Rapid Dose Therapeutics Corp’s market cap?

Rapid Dose Therapeutics Corp’s market cap is C$14.51M.

When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?

Rapid Dose Therapeutics Corp’s upcoming earnings report date is Jun 26, 2026 which is in 108 days.

How were Rapid Dose Therapeutics Corp’s earnings last quarter?

Rapid Dose Therapeutics Corp released its earnings results on Jan 29, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.

Is Rapid Dose Therapeutics Corp overvalued?

According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rapid Dose Therapeutics Corp pay dividends?

Rapid Dose Therapeutics Corp does not currently pay dividends.

What is Rapid Dose Therapeutics Corp’s EPS estimate?

Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rapid Dose Therapeutics Corp have?

Rapid Dose Therapeutics Corp has 131,886,760 shares outstanding.

What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?

Rapid Dose Therapeutics Corp reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?

Currently, no hedge funds are holding shares in TSE:DOSE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Rapid Dose Therapeutics Corp

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.